Oil Prices Surge Near $120 as U.S.-Iran Tensions Threaten Global Supply 
Gold Prices Dip Ahead of Fed Decision Amid Rising Middle East Tensions 
Iran-U.S. Conflict Escalation Threatens Global Oil Supply and Economic Stability 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Dollar Holds Near Two-Week High as Fed Hawkish Shift Lifts Yields, Yen Near Intervention Zone 
Markets Stay Strong Despite Oil Shock Concerns as Earnings Drive Investor Confidence 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
China Factory Activity Extends Growth in April Despite Global Pressures 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Yen Weakens After Intervention Spike as Dollar Stabilizes Amid Global Tensions 
Asian Stock Markets Rise Amid Wall Street Rally and U.S.-Iran Tensions 
Trump Urges Iran to Sign Nuclear Deal Amid Ongoing Conflict and Port Blockade 
Gold Prices Fall as Strong Dollar and Rising Oil Prices Pressure Markets 
South Korean drugmaker Daewoong Pharmaceutical Co. inked a US$430 million deal to provide US pharmaceutical venture firm Neurogastrx Inc. with its technology for fexuprazan, the novel drug candidate for gastroesophageal reflux.
The technology deal with Neurogastrx made the US the fourth country that the South Korean firm has signed technology deals with, after China, Brazil, and Mexico.
The said countries account for almost 40 percent of the global gastrointestinal disorder market.
The combined value of the deals is already over 1 trillion won.
Daewoong Pharmaceutical will also receive 13.5 percent of Neurogastrx's shares.
Daewoong Pharmaceutical claims that fexuprazan, a class of potassium-competitive acid blockers, exhibited a cure rate of 99 percent during the phase three clinical trials and is expected to win approval from local drug authorities soon.
Neurogastrx is a privately-held biopharmaceutical company that develops therapies for gastrointestinal disorders.
